NL-OMON25529
Completed
Not Applicable
The clinical evaluation of the effectiveness of two oral probiotic strains on gingival health.
Ir. W. Th. FokkemaACTA Dental Research B.V. (ADR)Gustav Mahlerlaan 30041081 LA Amsterdam, NLw.fokkema@acta.nl / +31 6 28 724 7880 sites117 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ir. W. Th. FokkemaACTA Dental Research B.V. (ADR)Gustav Mahlerlaan 30041081 LA Amsterdam, NLw.fokkema@acta.nl / +31 6 28 724 788
- Enrollment
- 117
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Willing and able to give written informed consent and willing and able to comply to all study procedures;
- •2\.Adult, ≥ 18 years \- 55 years;
Exclusion Criteria
- •1\.Not meeting the inclusion criteria;
- •2\.ACTA dental student or ACTA employee;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The clinical evaluation of the effectiveness of two oral probiotic strains on gingival health.mondgezondheidgum diseaseNL-OMON46824Academisch Centrum Tandheelkunde Amsterdam (ACTA)117
Completed
Not Applicable
A Clinical Study to evaluate the effect of two different combinations of BP medication in patients with uncontrolled BPCTRI/2018/08/015555Current Medical Concepts Pvt Ltd93
Recruiting
Phase 3
Comparison of the clinical effectiveness of the two different doses of Meropenem in pneumoniaIRCT20100107003014N19Sari University of Medical Sciences62
Active, not recruiting
Phase 1
A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis.EUCTR2018-000721-31-SEDepartment of Clinical Sciences, Karolinska Institutet Danderyd Hospital200
Active, not recruiting
Phase 1
A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis.Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2015-004116-38-SEDepartment of Clinical Sciences, Danderyd Hospital200